# Renegotiation Frictions and Financial Distress Resolution: Evidence from CDS Spreads

- **DOI:** [10.1093/rof/rfy021](https://doi.org/10.1093/rof/rfy021)
- **Rating:** Strong (4.1 out of 5)
- **Verdict:** A well-identified regulatory-shock study showing that taxing renegotiated debt at par raises bankruptcy risk, with local identification among large CDS-referenced firms its main constraint.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-14
- **Evaluation page:** https://www.nabu.science/paper/10.1093%2Frof%2Frfy021

## Strengths

- **Exogenous regulatory shock sharpens identification** TD9599's retroactive, syndicated-loan-specific, and unanticipated final form provides clean variation in out-of-court renegotiation costs, allowing the triple-differences design to separate renegotiation-friction effects from the selection effects that confounded prior proxy-based work.
  - Dimension: methodological rigour
  - Location: Sections 2.2, 3.1.2
- **Convergent evidence across three outcome layers** The paper documents a coherent chain from market anticipation (CDS spreads fall ~63 bp for distressed high-syndicate firms) to realized behavior (renegotiation rates more than double) to new contracting (lower markups and greater loan access), strengthening the inference beyond any single test.
  - Dimension: contribution
  - Location: Table 3; Table 5; Tables 6-7
- **Extensive falsification and robustness program** Jackknife replications, 39-block and 13-year placebos, parallel-trends verification, macro-confound checks, and internal-logic tests on lender tax rates and restructuring-inclusive CDS contracts collectively raise the bar against alternative explanations.
  - Dimension: methodological rigour
  - Location: Figures 5-9; Table 4 Panels A/B

## Limitations

- **Causal framing exceeds observational design** The paper repeatedly frames TD9599 as the cause of changes in bankruptcy risk and lending terms, while the design is a quasi-experimental observational comparison whose identifying assumptions cannot be fully verified from the data.
  - Dimension: methodological rigour
  - Location: Abstract; Sections 3.1.2, 3.2.2, 4.2, 5.2, 6.1
- **No formal unobserved-confounding sensitivity analysis** Despite strong placebo and parallel-trends evidence, the paper does not present a formal sensitivity analysis (e.g., an E-value) quantifying how robust the estimates are to an unmeasured contemporaneous shock.
  - Dimension: methodological rigour
  - Location: Section 3.2.4
- **Local identification limits generalizability** The CDS sample is restricted to 231 large firms with liquid CDS markets and the mechanism is a U.S.-specific IRS rule, so the magnitude estimates do not directly transfer to smaller firms, other debt markets, or other jurisdictions.
  - Dimension: application pathway
  - Location: Section 6.1

## Reliability checks

Caveats (4 of 4 checks).

- **Internal coherence:** Noted. Reported numbers are internally consistent (e.g., the triple-differences coefficient decomposition in footnote 11 sums correctly to -62.82 bp), and parallel-trends and placebo analyses are coherent with the design. The watch-out is that interpretation relies on the paper's causal framing of a single regulatory event, which is stronger than a quasi-experimental observational design can fully establish.
- **Research conduct:** Noted. No ethics approval is required for secondary market-data research, and no conflicts beyond a research-assistant acknowledgement are disclosed. Data and code are not made available and rely on proprietary single-source databases, which limits independent reproducibility; these are era- and field-appropriate absences rather than active concerns.
- **Reference integrity:** Clean. All 56 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
